USB

StoneCalibre, a Los Angeles-based private investment firm, announced this week that it has acquired Affymetrix's Anatrace business unit. Financial details of the deal were not disclosed.

By Ben Butkus
ArcticZymes, a Norwegian life science research tools firm specializing in cold-adapted and heat-labile enzymes for use in molecular biology and diagnostics, this week opened its first US office in the outskirts of Philadelphia.

This story was originally posted on Nov. 3
By Justin Petrone

Acknowledging the challenges the firm faces and admitting it has been "slow to respond to technology changes" in the market, Frank Witney said the firm still has some opportunities to restore growth — if it positions its products correctly.

To make up for the "lumpiness" of the market for genome-wide association studies, Affy will focus on applications that are downstream from GWAS, particularly in validation and routine testing, according to President and CEO Kevin King, who also shed some light on Affy's recent decision to sell its Clinical Services Laboratory to Navigenics.

People in the News

Premium

Frank Witney, Paul Keim, Trilochan Sahoo, Jack Lord, Mari Baker, Patrick Terry, Lutz Kirchrath

Affy transferred ownership of the 10,000-square-foot Clinical Services Lab to Navigenics earlier this year though an increasing number of drug makers outsource their molecular diagnostic research needs to CLIA labs.

People in the News

Premium

Frank Witney, Allen Bombard

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.